ABX474 is a precursor developed in cooperation with the Helmholtz Zentrum Dresden-Rossendorf (HZDR).[1]
It has been used for radiosynthesis of [99mTc]TcO-ABX474 in preclinical and clinical setup following local regulations and guidelines. Results have been published in: Rahbar et al. First Experiences with the new 99mTc labelled PSMA ligand [99mTc]TcO-ABX474 in Patients with Advanced Prostate Cancer Prior to PSMA targeted Radioligand Therapy. Journal of Nuclear Medicine June 2024, 65 (supplement 2), 241711.
[1] Lis et al. Development of [99mTc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer. Journal of Medicinal Chemistry 2025, https://doi.org/10.1021/acs.jmedchem.4c02767
Learn more about this compound and send us your quote request:
ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.
Based in Radeberg, Germany, and founded in 1997, our team of about 400 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards.
ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.
